Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a clinically available osteogenic growth factor. In its current form, approved for clinical use, however, the growth factor is delivered in excessively high doses, resulting in unpredictable bone growth and unwanted clinical side effects. In this study, we evaluated a novel system, slow-release hybrid delivery system for PLGA- rhBMP-2 microcapusles in combination with BM MSC spheroids, and assess if it can lead to improved BMP-derived bone formation.
Recognize the challenges of growth factor delivery for bone tissue engineering.
Discuss the role of mesenchymal stem cells (MSCs) and recombinant human bone morphogenetic protein-2 (rhBMP-2) for future growth factor delivery systems.
Discuss the advantages and applications of culturing MSCs in 3D Spheroids.